Should Investors Trust The Upside Potential In Alaunos Therapeutics Inc. (TCRT)?

Alaunos Therapeutics Inc. (NASDAQ:TCRT) currently has a daily average trading volume of 634.07K but it saw 892539 shares traded on Thursday. With a market cap of 138.57M USD, stock’s current market price of $0.60 came rising about 1.69 while comparing to the previous closing price of $0.59. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.01 and as low as $0.45. In the recent trading on the day, stock has struck highest price mark of $0.625 while lowest mark touched by it was $0.5896.

Taking a look at 20-day trading activity of Alaunos Therapeutics Inc. (TCRT) gives us an average price of $0.6028, while its current price level is -85.04% below from 52-week high level whereas it is 32.80% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.5697 while that of 200 days or SMA-200 reads an average of $1.0490. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.27% during that period while stretching the period over a month that increases to 8.35%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 51.11 which implies that the stock is in neutral territory.

Alaunos Therapeutics Inc. (TCRT)’s stock is currently under the radar of 6 analysts who are in consensus at a 12-month price target range of between $0.70 and $7.50 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $0.70 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $7.50. Average price target assigned by them is $3.03 which highlights an upside potential of 80.2% for the stock over that period. And to attain the median price target of $2.50 assigned by those analysts, stock has to add about 76.0% of value to its current levels.

Data by FactSet Research shows that 6 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 5 analysts suggested the investors to Buy the stock while 1 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Moderate Buy.

Over the week, TCRT’s stock price is moving -0.78% down while it is 11.11% when we observe its performance for the past one month. Year-to-date it is -7.56% down and over the past year, the stock is showing an upside performance of 21.16%.

The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.04 beat the consensus estimate of -$0.04 for the same. The company is expected to be releasing its next quarterly report in 08/10/2023, for which analysts forecasted an EPS of -$0.04 while estimate for next year EPS is -$0.17.

Currently, Alaunos Therapeutics Inc.’s total number of outstanding shares is 239.68M with 8.86% of that held by the insiders while 33.22% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -63.40% and return on equity (ROE) at -108.30%. Stock’s beta reads 0.16. Stock has a price to book (P/B) ratio of 5.00 while price to sale or P/S ratio amounts to 47.78. Its return on asset (ROA) is -59.60% on average.

In the most recent quarter, JPMorgan Funds – Thematics – Gene came cutting its stake by -40.38% in the company and now holds 2.51 million or 1.04% of the company’s stake having worth of about 1.43 million.